Clinical monitoring GLP-1 therapy requires medical supervision, dose adjustment, and monitoring for adverse effects
For the HEDS assays, either GSH was varied between 100 M and 1.5 mM for ScGrx (or 250 M and 3.0 mM for PfGrx) at fixed concentrations of HEDS (0.18, 0.37, 0.55 and 0.74 mM) or HEDS was varied between 90 and 920 M at fixed concentrations of GSH (0.3, 0.5, 1 and 1.5 mM for ScGrx7 or 0.25, 0.5, 1 and 2 mM for PfGrx)
Zhou JY, Poudel A, Welchko R, et al
The ideal candidate will also have a healthy endocrine system, not be pregnant or breastfeeding, and have no history of severe low blood sugar
Around 91% of those affected in one review analysis already had a history of hair loss
doi: 10.1053/j.gastro.2016.02.032 11 CassarGEYoussefGJKnowlesSMouldingRAustinDW